IDHIFA failed to demonstrate improved OS in adult patients with late stage AML and an IDH2 mutation versus conventional care regimens in a Phase 3 confirmatory study evaluating efficacy and safety. Do not initiate IDHIFA in new patients. IDHIFA is available through Health Canada’s SAP for patients who require continued treatment.
RecallTracker